$APOP .55 DIP DON'T MISS NEWS 1/2 Trial Passes Saf
Post# of 145125
(Total Views: 113)
Posted On: 08/13/2019 10:31:01 AM
$APOP .55 DIP DON'T MISS NEWS 1/2 Trial Passes Safety Hurdle;
All Content and Data provided by Third-Parties — Terms of Use
Cellect Biotechnology Phase 1/2 Trial Passes Safety Hurdle; Up 45% Pre-Bell
MT NEWSWIRES 8:52 AM ET 8/12/2019
Symbol Last Price Change
APOP 0.5423up -0.0377 (-6.5%)
QUOTES AS OF 10:26:11 AM ET 08/13/2019
08:52 AM EDT, 08/12/2019 (MT Newswires) -- Cellect Biotechnology(APOP) , a company active in stem-cell therapies, said pre-bell Monday that a phase 1/2 trial of its ApoGraft therapy has passed a safety hurdle, allowing the trial to proceed to include additional patients.
Shares of the Israel-based company jumped 45% to $0.60 ahead of the opening bell.
The ApoGraft therapy is aimed at limiting "graft versus host" maladies that can occur after cell transplants,
Cellect Biotechnology (APOP) said that following a trial-data review of the ApoGraft trial, the Data and Safety Monitoring Board unanimously recommended dose escalation and the continuation of enrollment for the fourth and final dose cohort in the study."
The company said it expects to complete patient recruitment for the ApoGraft trial by the end of 2019 and to release data in H1 2020. The primary endpoint of the study is to evaluate the overall incidence, frequency, and severity of adverse events potentially related to ApoGraft at 180 days after transplant.
The company also said it plans a US clinical trial with Washington University.
Price: 0.6100, Change: +0.20, Percent Change: +46.99
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
©http://www.mtnewswires.com Copyright © 2019 MT Newswires. All rights reserved.
APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP
Read More: https://investorshangout.com/post/newpost/690...z5wUXmPqCo
All Content and Data provided by Third-Parties — Terms of Use
Cellect Biotechnology Phase 1/2 Trial Passes Safety Hurdle; Up 45% Pre-Bell
MT NEWSWIRES 8:52 AM ET 8/12/2019
Symbol Last Price Change
APOP 0.5423up -0.0377 (-6.5%)
QUOTES AS OF 10:26:11 AM ET 08/13/2019
08:52 AM EDT, 08/12/2019 (MT Newswires) -- Cellect Biotechnology(APOP) , a company active in stem-cell therapies, said pre-bell Monday that a phase 1/2 trial of its ApoGraft therapy has passed a safety hurdle, allowing the trial to proceed to include additional patients.
Shares of the Israel-based company jumped 45% to $0.60 ahead of the opening bell.
The ApoGraft therapy is aimed at limiting "graft versus host" maladies that can occur after cell transplants,
Cellect Biotechnology (APOP) said that following a trial-data review of the ApoGraft trial, the Data and Safety Monitoring Board unanimously recommended dose escalation and the continuation of enrollment for the fourth and final dose cohort in the study."
The company said it expects to complete patient recruitment for the ApoGraft trial by the end of 2019 and to release data in H1 2020. The primary endpoint of the study is to evaluate the overall incidence, frequency, and severity of adverse events potentially related to ApoGraft at 180 days after transplant.
The company also said it plans a US clinical trial with Washington University.
Price: 0.6100, Change: +0.20, Percent Change: +46.99
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
©http://www.mtnewswires.com Copyright © 2019 MT Newswires. All rights reserved.
APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP APOP
Read More: https://investorshangout.com/post/newpost/690...z5wUXmPqCo
(0)
(0)
I ONLY POST WHAT I PLAY